Noninvasive imaging plays an emerging role in preclinical and clinical cancer research and has high potential to improve clinical translation of new drugs. This article summarizes and discusses tools and methods to image tumor angiogenesis and monitor anti-angiogenic therapy effects. In this context, micro-computed tomography ( CT) is recommended to visualize and quantify the micro-architecture of functional tumor vessels. Contrast-enhanced ultrasound (US) and magnetic resonance imaging (MRI) are favorable tools to assess functional vascular parameters, such as perfusion and relative blood volume. These functional parameters have been shown to indicate anti-angiogenic therapy response at an early stage, before changes in tumor size appear. For tumor characterization, the imaging of the molecular characteristics of tumor blood vessels, such as receptor expression, might have an even higher diagnostic potential and has been shown to be highly suitable for therapy monitoring as well. In this context, US using targeted microbubbles is currently evaluated in clinical trials as an important tool for the molecular characterization of the angiogenic endothelium. Other modalities, being preferably used for molecular imaging of vessels and their surrounding stroma, are photoacoustic imaging (PAI), near-infrared fluorescence optical imaging (OI), MRI, positron emission tomography (PET) and single photon emission computed tomography (SPECT). The latter two are particularly useful if very high sensitivity is needed, and/ or if the molecular target is difficult to access. Carefully considering the pros and cons of different imaging modalities in a multimodal imaging setup enables a comprehensive longitudinal assessment of the (micro)morphology, function and molecular regulation of tumor vessels.
Introduction
Angiogenesis is one of the hallmarks of cancer and anti-angiogenic therapy concepts play an important role in modern tumor treatment [1] [2] . Tumors above a critical size of 2-3 mm 3 are strongly dependent on the active recruitment of new blood vessels [3] [4] . Tumor angiogenesis is regulated by a plurality of proteins including pro-angiogenic factors, growth factor receptors and ECM-binding proteins like integrins [5] . Furthermore, the vascular between 4 s and 30 min in small animal imaging studies. This results in tolerable X-ray doses between 20 and 300 mGy, and a spatial resolution ranging between 20 and 200 m voxel side length ( Figure 1A ) [15] .
A rapid but precise visualization of blood vessels significantly depends on the chosen contrast agent. Due to their small size, clinically used contrast agents extravasate and CT angiography imaging has to be done during the first circulations in the body. However, due to the high viscosity of CT contrast agents, this often leads to complications during i.v. injection and sometimes even to vessel rupture in small animals. Alternatively, experimental and commercial polyiodinated triglyceride emulsions with long blood half-life times are available [16] [17] [18] . However, when using blood pool CT contrast agents care should be taken to assure that the iodine concentration in the injection solution is sufficiently high (based on our own experience at least 130 mg iodine per ml are required for the visualization of microvessels). In such cases, the intravenous administration of the contrast agent can be performed prior to the CT scan, if the scan is performed immediately afterwards [19] . Alternatively, for dynamic analyses, a catheterization of the animals enables a constant application (infusion) of the contrast agent during the scan, allowing a more complex pharmacokinetic analysis and the extraction of additional functional parameters. Dynamic contrast-enhanced CT (DCE-CT) imaging was for instance performed by Eisa and colleagues, who investigated the anti-angiogenic effect of the mTOR inhibitor Afinitor (everolimus) in orthotopic MCF-7 mammary cancer xenografts [20] . After mice had undergone DCE-CT, functional parameters like the rBV, vascular permeability (K) and area under the time-enhancement curve (AUC) were calculated for the total, peripheral and central tumor volumes of interest (Figure 2A ). They could demonstrate that the mean AUC was significantly lower in Afinitor-treated tumors than in control tumors. However, significant differences for rBV and K could only be observed for peripheral tumor regions.
In another experimental setting, Tai et al. investigated the effects of the multi-tyrosine kinase inhibitor vandetanib in subcutaneous LoVo human colon carcinoma-bearing nude rats using DCE-CT. It was shown that 24 h after the therapy started, vandetanib significantly reduced tumor blood flow (BF) and rBV, but not mean transit time (MTT) and vascular permeability; vehicle treatment had no significant effect on the determined parameters [21] . An overview of vascular parameters that can be assessed using contrastenhanced CT is given in table 3. However, by using DCE-CT, it should be taken into consideration that this technique still suffers from beam hardening artifacts originating e.g. from bones or highly contrasted large vessels.
For analyzing microvessels in bone metastases, and for distinguishing between radiopaque bone structures and contrast-enhanced microvessels, dual-energy CT approaches can be applied, both, preclinically and clinically [22] [23] . Dual-energy CT is based on two X-ray beams with different energy compositions. Due to X-ray energy-dependent absorption characteristics of bone structures and contrast-enhanced blood vessels, blood vessels can be specifically detected and quantified even inside radiopaque bone structures. The dual energy CT technique was for example applied by Gremse et al., who used it to assess vascular inflammation and stenosis in mice [24] .
High-resolution ex vivo CT imaging techniques can be used for generating and analyzing 3D images of the micro-architecture of the tumor vasculature with a spatial resolution of less than 5 m voxel side length. For this approach, Savai and colleagues perfused mice with orthotopic lung carcinoma tumors with Microfil® (i.e. a lead-containing silicone rubber suspension, which polymerizes intravascularly). After tumor harvesting and scanning in a high-resolution CT system, a significant reduction of small blood vessels was observed in bevacizumab-treated vs. untreated tumors [25] . Such casting methods provide important information on the 3D micro-morphology of the tumor vasculature, enabling e.g. the Ehling 
Europe PMC Funders Author Manuscripts
Europe PMC Funders Author Manuscripts assessment of blood vessel size, blood vessel distribution and blood vessel branching (3D morphology of tumor microvessels is exemplified in an A549 human lung adenocarcinoma xenograft in Figure 1B ).
Alternatively, intravital microscopy approaches such as multiphoton microscopy (MPM) and optical frequency domain imaging (OFDI) using tumors grown in dorsal skin fold chambers can be used for such purposes, i.e. for studying the 3D micro-morphological aspects of tumor angiogenesis. The dorsal skin fold chamber technique was initially described in rats by Papenfuss and colleagues [26] and was used for long-term imaging of tumor blood vessels for instance by Leunig and Lichtenfeld [27] [28] . Using this technique, a detailed comparison between MPM and OFDI for investigating the micro-architecture of tumor blood vessels in vivo was performed by Vakoc and colleagues [29] . In particular using OFDI, they showed that the VEGFR-2 blocking monoclonal antibody DC101 longitudinally leads to a significant reduction of mean intratumoral vessel length and diameter in murine mammary adenocarcinoma tumor xenografts. Surprisingly, angiogenesis-related parameters like tortuosity or fractal dimension did not alter upon treatment [29] . The cranial window model is another technique for long-term intravital imaging of blood vessels of cerebral tumors exploiting a high optical transparency. This model was, for instance, used by Hansen-Algenstaedt and colleagues for the non-invasive visualization of tumor blood vessels in tumor xenografts of the brain [30].
Magnetic Resonance Imaging
Advantages of MRI are its high spatial resolution, excellent soft tissue contrast and a broad arsenal of methods that can be applied to functionally characterize tissues. The latter include both, non contrast-enhanced techniques, such as spectroscopy (MRS; to investigate cell metabolism), diffusion weighted imaging (DWI; measuring cellularity), time of flight (TOF) angiography, arterial spin labeling (ASL; to visualize vessels and monitor perfusion), blood oxygenation level dependent imaging (BOLD; to assess vessel oxygenation, vessel responsiveness and maturity), as well as contrast enhanced methods like dynamic contrast enhanced MR imaging (DCE-MRI, to assess rBV, perfusion and permeability) and vessel size imaging (VSI; to quantify the mean vessel diameter within tissues) [31] .
DWI and MRS are methods to assess tissue cellularity and metabolism and there are a number of review articles about their use for cancer characterization [32] [33] . ASL is based on radiofrequency pulses which excite the nuclear spin of inflowing arterial protons, resulting in magnetic labeling of the inflowing blood. Using this endogenous contrast, ASL can be used to assess blood flow and tissue perfusion. Similarly, TOF angiography visualizes vessels by the signal change that occurs when magnetized protons in the blood leave the image voxel during the measurement [34] . Although the non-contrast-enhanced visualization of tumor vessels by TOF and ASL improves when using MRI devices operating at higher field strength, vessels with very slow blood velocities cannot be reliably depicted (cf. Doppler ultrasound). Since especially these vessels respond to anti-angiogenic therapies, contrast-enhanced T1-weighted angiography and DCE-MRI are generally preferred for therapy monitoring.
Using MR angiography in combination with gadolinium-based blood pool contrast agents, vessels as small as 30 -100 m in diameter can be visualized [14, 31, 35] . DCE-MRI in combination with quantitative pharmacokinetic analyses provides information on vascular parameters like blood flow, rBV, regional distribution volume of the contrast agent (rDV), MTT, tissue perfusion and changes in vessel permeability (cf. 
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Europe PMC Funders Author Manuscripts before changes in tumor size became apparent ( Figure 2C ) [36] . In addition to subcutaneous tumors, DCE-MRI has also been shown to work reliably for monitoring orthotopic tumors and even metastases [37] [38] . DCE-MRI has furthermore been successfully applied in several clinical trials focusing on anti-angiogenic therapy, e.g. in investigating the therapeutical effects of PTK/ZK (a VEGFR tyrosine kinase inhibitor) in patients with colorectal cancer and liver metastases, of axitinib (AG-013736; a multi-target tyrosine kinase inhibitor) in patients with advanced solid tumors, and of bevacizumab in patients with breast cancer [39] [40] [41] .
An MRI technique capable of obtaining anatomical information of blood vessels on the micro-morphological scale is vessel size imaging (VSI). VSI is based on the measurement of T2 and T2* relaxation times before and after the intravenous injection of a superparamagnetic contrast agent. While the T2 relaxation time is dependent on water diffusion, and therefore on the size and number of vessels per voxel, changes in the T2* relaxation time are mostly dependent on the amount of contrast agent per voxel. With these two pieces of information, it is possible to calculate the mean vessel diameter of tissues [42] .
Reports on the changes of mean vessel diameters in tumors during anti-angiogenic therapy have provided contradictory results. On the one hand, investigating the anti-angiogenic effects of sunitinib in A431 xenografts and of bevacizumab in HaCaT-ras-A-5RT3 xenografts, Zwick and colleagues analyzed treatment-induced changes in tumor vascularity by DCE-MRI and VSI [43] . In both tumor models, the mean vessel size increased as a result of therapy, which can be explained by the fact that the vessels responding to treatment are mostly small and immature, and that larger and more mature vessels persist after therapy. On the other hand, when using the vascular disrupting agent ZD6126 to treat prostate cancer xenografts, decreases in vessel size indices were observed [44] . Reasons might be differences in the vascular architecture in the different tumor models used (e.g. larger immature vessels), or differences in the mechanism of action of the anti-vascular agents used.
Another approach for longitudinally analyzing anti-angiogenic therapy effects in tumors dependent on vessel maturation is BOLD MRI. The BOLD contrast derives from the different relaxation characteristics of oxygenated and de-oxygenated hemoglobin in the blood. The inhalation of oxygen can be used to induce a signal change in the blood and thus to characterize tissue vascularization. Also the response of vessels to hypercapnia vs. hyperoxia can be studied. By this, information about vascular maturity is obtained since only mature vessels associated with periendothelially localized contractile mural cells functionally respond to elevated levels of CO 2 (hypercapnia). As an example, inhaling air with a CO 2 content of 5% leads to a selective contraction of mature vessels, which results in specific MR signal changes [45] [46] . In a novel approach, Cai and co-workers investigated the BOLD effect under different levels of oxygen inhalation for the development of MR BOLD angiography ( Figure 1 G-H) [47] .
For molecular imaging, numerous molecular MR probes have been developed to monitor tumor angiogenesis. Among the most frequently used ones are antibody-or peptide-coated ultrasmall superparamagnetic iron oxide nanoparticles (USPIOs) [48] [49] and Gd-loaded paramagnetic liposomes [50] [51] . The design, structure and application of different types of MR contrast agents are reviewed in [52] . In addition, there are few reports on lowmolecular-weight probes binding to integrins [53] , thrombin, fibrin or elastin [54] . Although it has been shown that using RGD-coated USPIO, squamous cell carcinomas with high vs. low levels of integrin expression on tumor blood vessels can be distinguished [55] , and that anti-angiogenic therapy effects can be monitored with paramagnetic liposomes [51] , there still is a debate on the reliability of the method and its usefulness for biological and medical research. 

Ultrasound Imaging
Ultrasound is one of the most frequently used tomographic clinical imaging modalities. In preclinical settings, high-frequency US enables a real-time acquisition of functional and molecular information with high temporal and spatial resolution.
Power Doppler US is used as a method for studying anti-angiogenic therapy effects based on echo frequencies coming from moving elements, e.g. circulating blood cells. For this technique, no contrast agent has to be injected ( Figure 1E ). It allows the quantification of blood flow and the visualization of tumor vascularization. However, it should be noted that the sensitivity of Power Doppler US is not sufficient to depict small vessels (<100 m) with low flow velocities [56] . In particular, this has to be seen critical if anti-angiogenic therapy effects should be assessed and quantified in tumors, which contain mainly small and immature blood vessels with slow flow velocities. Nevertheless, several groups have been able to demonstrate that contrast-enhanced Power Doppler US is capable of quantifying anti-angiogenic therapy effects in preclinical in vivo tumor models [57] [58] [59] .
With the help of gas-filled microbubbles (MB), the assessment of the architecture of tumor blood vessels as well as of functional or molecular parameters can be improved ( Figure 1F ). Gas-filled MB increase the difference in the acoustic impedance between contrast-enhanced and non-enhanced tissues, and can be detected with high sensitivity and specificity [56] . Unspecific gas-filled MB are used as a contrast agent for the visualization (Figure 1 C-D) and quantification of blood velocity, perfusion and the relative blood volume (rBV) ( Figure  2B ) in tumors [60] [61] . Specific antibody-or peptide-modified MB are used for molecular US imaging of angiogenesis-related markers ( Figure 3A -C).
After the intravenous injection of MB, which remain strictly intravascular because of their large size, the following parameters are generally calculated from the signal intensity vs. time curve: the maximum peak enhancement, the up-slope, the delay time and the area under curve. It has been shown that the maximum peak in color pixel density and the accumulated maximum intensity over time correlate well with the rBV in tumors, and that the up-slope of the intensity curve correlates with perfusion [56] . Based on these parameters, several studies have been performed employing contrast-enhanced functional US for the quantification of anti-angiogenic therapy effects, showing a significant correlation in the assessment of therapy response with post-mortem histology. The tumor rBV was determined from the change in signal intensity after MB injection, indicating in the vast majority of cases that anti-angiogenic therapies lead to significant reduction of rBV in comparison to non-treated animals, and that these effects correlate with the microvessel density (MVD) determined by histology [56, [62] [63] . Palmowski and colleagues used a combination of 3D non-contrastenhanced and contrast-enhanced Power Doppler US for longitudinal monitoring antiangiogenic effects of sunitinib in A431 epidermoid carcinoma-bearing mice. Because contrast-sensitive US recognizes all vessels, whereas flow-sensitive non-contrast-enhanced Doppler US predominantly captures mature vessels, a selective response of different vessel fractions and thus vascular maturation during anti-angiogenic therapy could be assessed ( Figure 2B ) [64] .
Another method to quantify rBV and perfusion is via destruction-replenishment analysis. This is based on the destruction of MB at a stable blood concentration phase in the imaged area by high-energy US pulses and on the subsequent measurement of the re-entry of circulating MB into the vascularized region of interest. This enables the quantification of blood velocity and perfusion. Krix and co-workers adapted this method to be applicable after bolus injection of MB and showed in squamous cell carcinoma xenografts that effects of the anti-VEGFR-2 antibody DC101 can be mirrored faithfully [65] . 
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Molecular US imaging is frequently applied to non-invasively study tumor angiogenesis and anti-angiogenic therapy effects. During tumor growth, receptor structures such as VEGFR-2 or v 3 integrins are highly overexpressed on endothelial cells within tumor blood vessels. For molecular US imaging, MB can be functionalized with targeting moieties which enable specific binding to these endothelial cell markers upon intravenous MB administration ( Figure 3A ). Different procedures for labeling MB with specific antibodies or peptides have been described, based either on the direct incorporation or chemical coupling, or indirectly via strept(avidin)-biotin interactions [56, [66] [67] . The specific accumulation of targeted MB at pathological sites can be assessed by a signal subtraction method (pre minus post a destructive pulse, Figure 3B ) or by Sensitive Particle Acoustic Quantification (SPAQ, Figure 3C ) [56] . Molecular US imaging sensitively indicated changes in VEGFR-2 or v 3 integrin expression during therapeutic inhibition of matrix metalloproteinases [68] and early vascular inflammation after heavy ion therapy using MB targeted to ICAM-1 and v 3 integrin [69] [70] . However, since such molecular information generally does not allow differentiation between changes in marker expression on the endothelial surface and changes in blood vessel density in tumors, functional and molecular US should be combined, and a normalization of the molecular data on the basis of the functional data (rBV) should be performed [71] .
Optical and Photoacoustic Imaging
Optical imaging is based on the detection of light, which is emitted from injectable probes or heterologous proteins inside the body after illumination with excitation light. Emission wavelengths of the near-infrared fluorochromes ranging between 650-950 nm are generally preferred, resulting in minimized tissue absorption and low levels of autofluorescence. Several planar and tomographic near-infrared fluorescence OI modalities have been developed in the last decade, primarily for the in vivo monitoring of molecular targets. In this context, planar optical reflectance imaging (ORI) systems allow semi-quantitative analyses, while tomographic methods such as fluorescence molecular tomography (FMT) are more quantitative and less penetration depth-dependent, resulting in a spatial resolution of 1 mm voxel side length [72] . However, due to the lack of morphological information, it is a great advantage to choose a hybrid optical imaging approach as presented in [73] [74] , in order to have better anatomical assignment of the fluorescent signals, and to improve optical image reconstruction by considering information from the mouse anatomy.
Several optical blood pool agents [75] [76] as well as optical probes targeting VEGFR-2 or v 3 integrin in tumors [77] [78] [79] have been designed and evaluated, and have demonstrated the potential of planar and tomographic OI for monitoring the efficacy of anticancer therapy. For instance, Lederle et al. used an annexin-based fluorescent probe to monitor apoptosis in A431 epidermoid carcinoma xenografts treated with sunitinib using FMT ( Figure 3D ). Additionally, tumor vascularization was investigated by FMT using an optical blood pool marker and by contrast-enhanced US. Vascularization significantly decreased in treated tumors, however no enhanced annexin accumulation was observed although the gold standard TUNEL staining indicated increased apoptosis. It was shown that the rapid breakdown of vascularization during anti-angiogenic therapy impaired the delivery of annexin and thus resulted in seemingly lower apoptosis rates [76] . This clearly shows that molecular imaging of extravascular targets can fail if vascular physiology dramatically changes and illustrates the need to acquire both, functional and molecular information in order to avoid data misinterpretation.
Bioluminescence imaging (BLI) enables the non-invasive and longitudinal assessment of tumor growth, metastasis, angiogenesis and gene expression in vivo using a reporter gene approach. In this context, the bioluminescent reporter system is mainly luciferase reacting 
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Europe PMC Funders Author Manuscripts with a substrate (e.g. luciferin) and resulting in emitted light with an emission spectrum between 480 nm and 611 nm. An overview of bioluminescence instruments, gene reporter systems and fluorescent probes is given by Snoeks et al. [80] . For studying effects of VEGFR-2 on tumor angiogenesis and for monitoring VEGFR-2 gene expression in vivo, Zhang and colleagues established a VEGFR-2-luciferase transgenic mouse model (FVB/ NTg(VEGFR2-luc)-Xen) [81] . Red and green fluorescent tumor cells were inoculated in a VEGFR2-luc knock-in mouse, enabling the simultaneous imaging and quantification of tumor growth, as well as the non-invasive assessment of angiogenesis [80] . For similar purposes, transgenic mouse models expressing GFP [82] or luciferase under control of the VEGF promoter [83] are available, as well as Tie2-GFP and eNOS-GFP reporter mice [80] .
Due to the fact that during tumor growth, hypoxia and the subsequent stabilization of hypoxia inducible factor-1 (HIF-1) play key roles in the induction of angiogenesis, several luciferase or GFP reporter constructs were established which are driven by the hypoxia responsive element (HRE), i.e. the HIF-1 target binding site. These HRE-reporter constructs have been demonstrated to be valuable tools to non-invasively evaluate tumor hypoxia and the efficacy of hypoxia-directed therapies [80] .
Photoacoustic imaging (PAI) is a relatively young imaging technique, which is based on the thermoelastic expansion of molecules after light absorption and thus the conversion of optical to ultrasonic energy. PAI can provide morphological, functional, and molecular information and even fluorescent reporter genes can be used [84] . Due to its strong optical absorption, hemoglobin can be used as an intrinsic contrast agent to visualize vessels in combination with quantitative functional information on absolute blood oxygen saturation and blood flow [85] . De la Zerda and co-workers investigated first the potential of PAI in preclinical tumor models for the visualization and quantification of tumor angiogenesis using novel photoacoustic contrast agents that are based on the binding of small optical dyes and RGD peptides to single-walled carbon nanotubes (SWNT-dye) [86] . For investigation of the potential of PAI for the in vivo visualization and quantification of tumor angiogenesis and tumor growth at the microscopic level, Cai and colleagues inoculated lacZ-marked 9 L gliosarcoma tumor cells into mice. Tumors were non-invasively and simultaneously imaged by dual-wavelength acoustic-resolution photoacoustic microscopy: lacZ-expressing tumor cells by optical imaging at a 635 nm wavelength and the tumor surrounding microvasculature by photoacoustic imaging at a 584 nm wavelength [87] . These data suggest that PAI may establish as a complementary tool to conventional optical fluorescence imaging of reporter genes for the in vivo assessment of therapy effects on total tumor volume and tumor microvasculature. PAI is a translational imaging modality and first clinical studies have demonstrated its potential application for imaging melanoma tumors, gastrointestinal tract endoscopy, intravascular catheter imaging, neonatal brain imaging, breast cancer detection, prostate cancer detection, sentinel lymph node imaging, blood perfusion and oxygenation imaging [84] .
Positron Emission Tomography and Single Photon Emission Computed Tomography
For the identification and quantification of molecular processes and targets involved in the development and progression of cancer and tumor angiogenesis at the picomolar to nanomolar level, positron emission tomography (PET) and single photon emission computed tomography (SPECT) are the modalities of choice. Both play a major role in the preclinical development of novel targeted drugs and in clinical cancer diagnosis and therapy monitoring. While PET is based on the co-incidence of two -photons with 511 keV, SPECT measures single gamma photons with isotope-specific energies (e.g. 99m Tc, 111 In, 123 I and 201 TI). This enables measuring different tracers simultaneously and also tracers with a 
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For molecular imaging of tumor angiogenesis using PET, a number of radioactive tracers targeting angiogenesis-related markers such as growth factors, tyrosine kinase receptors and integrins, have been developed (for a detailed overview of radiolabeled anti-VEGF/VEGFR and antiv 3 tracers, see Cai et al. [88] ). As an example, VEGF 121 was radiolabeled with 64 Cu, and it was demonstrated that 64 CU-DOTA-VEGF 121 had a rapid and specific uptake in highly vascularized small U87MG glioma xenografts, with high levels of VEGFR-2, and a significantly lower uptake in large U87MG tumors, which expressed low levels of VEGFR-2 [89] . Also SPECT imaging of VEGF receptors was described to characterize tumor angiogenesis and to assess anti-angiogenic therapies in several preclinical approaches [88] .
In several studies, PET radiotracers with 18 F-, 68 Ga-, and 64 Cu-labeled RGD were utilized for v ß 3 integrin imaging, to quantify angiogenesis at the molecular level [90] [91] .
Similarly, 99m Tc-labeled RGD probes were used to assess v ß 3 expression in experimental gliomas [92] . Yang et al. treated orthotopic MDA-MB-435 tumor-bearing mice with the VEGFR-2 tyrosine kinase inhibitor ZD4190 and could demonstrate that the proliferationspecific 18 F-FLT and integrin-specific 18 F-FPPRGD2 uptake in tumors treated with ZD4190 were significantly lower than in control animals, and correlated with immunohistochemical findings from CD31, CD61 and Ki-67 stainings [93] . In another study, Jin and co-workers demonstrated that integrin imaging by 64 Cu-cyclam-RAFT-c(-RGDfK-)4 PET indicates response of human hepatocellular carcinoma xenografts to a novel multi-targeted tyrosine kinase inhibitor, and that the change in tracer uptake correlates well with histological microvessel density [94] .
In the clinical context, anti-angiogenic therapy effects are mostly assessed using clinically established radiotracers, reporting on tumor cell metabolism and proliferation. For example, 18 F-FDG PET (indicating glucose uptake and hexokinase activity) was used for therapy monitoring of GIST (gastrointestinal stromal tumors) in patients treated with imatinib or sunitinib [95] . In a recent clinical study focusing on glioma treatment with bevacizumab, Schwarzenberg and co-workers demonstrated that 18 F-FLT PET is a sensitive indicator of therapy response and that a change in tracer uptake is a decent indicator of progression-free survival ( Figure 3E ) [96] . In a molecular approach, Metz and co-workers examined patients with primary or metastasized lung cancer with DCE-MRI and with PET using 18 F-galacto-RGD and 18 F-FDG PET. They could demonstrate that an early therapy response can be assessed by PET imaging using 18 F-galacto-RGD but not 18 F-FDG tracers, and that these data correlate with findings from DCE-MRI [97] . In breast cancer patients using SPECT, Bach-Gansmo and co-workers investigated the potential of the integrinspecific 99m Tc-NC100692 tracer and could demonstrate that 19 of 22 malignant lesions were detected using 99m Tc-NC100692 scintigraphy [98] . In a theranostic approach, the accumulation of 11 C-docetaxel after administration of bevacizumab was studied, in order to investigate whether vascular normalization induced by VEGF-inhibition leads to a better accumulation of the radiolabelled drug. Unfortunately, the opposite was observed, clearly demonstrating the need for individual therapy scheduling and optimized dosing of antiangiogenic drugs in combination therapy schedules [99] .
Conclusions
Over the last years, many promising non-invasive imaging techniques have been developed which enable a reliable characterization of blood vessels within tumors. Many of these techniques could be translated to the clinic and now form an important link between preclinical and clinical cancer research. In this context, it has clearly been shown that noninvasively determined functional and/or molecular vascular parameters are often earlier and more reliable indicators of therapy response than tumor size measurements. Nevertheless, the optimal implementation of non-invasive angiogenesis imaging into preclinical research and clinical diagnosis (for therapy monitoring) can only occur if the obtained parameters are clearly understood in relation to the underlying tumor biology. Functional and molecular parameters are often required together to understand vascular remodeling. This does not always require a multimodal but often a multi-parametric approach. In this context, the choice of tools should be based on the aim to combine the best working modalities and methods providing the most reliable quantitative measures, thereby generating minimal costs and requiring as less time as possible. In particular for facilitating clinical translation and for individualizing (chemo-) therapeutic interventions, it is of significant importance to adapt the therapeutic protocol (e.g. choice of drug, dosing regimen, treatment change, etc) on the basis of the results obtained using non-invasive imaging. Such theranostic concepts, i.e. direct and tight combinations of disease diagnosis and therapy, are considered to be highly important for realizing the potential of personalized medicine. After inducing hypoxia via the inhalation of 8% oxygen, BOLD contrast generates highresolution maps of normal brain (G) and tumor brain vasculature (H) using a 9.4 Tesla scanner. For investigating micro-morphological aspects, maximum intensity projection (MIP) images can be obtained, which clearly show differences in symmetry and density of blood vessels in brain tumors vs. healthy brain tissue (reproduced with permission from [47] ).
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Figure 2. Functional imaging of tumor angiogenesis
A: Dynamic CT imaging is highly suitable for assessing anti-angiogenic therapy effects. During the CT scan, a blood pool contrast agent is injected intravenously. After tumor segmentation and determination of different volumes of interest (VOI) within the tumor (e.g. total tumor volume vs. tumor center vs. tumor periphery), dynamic contrast-enhanced CT imaging can be employed to longitudinally quantify differences between treated and nontreated animals (reproduced from [20] with kind permission from Springer Science + Business Media). B: Another method for non-invasively assessing anti-angiogenic therapy effects, especially those depending on the maturity of tumor blood vessels, relies on the combination of contrast-enhanced and non-contrast-enhanced high-frequency volumetric 
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Power Doppler US. Because contrast-sensitive US is more sensitive for small immature vessels (primarily in the tumor center in this particular example), whereas flow-sensitive non-contrast-enhanced US mostly captures large and mature vessels (primarily in the tumor periphery), the combination of both methods can provide non-invasive feedback on blood vessel maturation in tumors during anti-angiogenic treatment. As early as 3 days after the beginning of anti-angiogenic treatment with sunitinib in mice with subcutaneously inoculated A431 tumors, a regression of immature vessels in the tumor center can be observed, while large and mature vessels at the tumor periphery are only partially affected (data from [64] ). C: A third modality which is highly suitable for visualizing and quantifying anti-angiogenic therapy effects is DCE-MRI. Upon treating mice bearing subcutaneous squamous cell carcinoma xenografts, anti-angiogenic therapy with the VEGFR-2-blocking antibody DC 101, representative parameter maps of the amplitude A were acquired over a 4 day period. Changes in the amplitude, assessed using the Brix model, are shown in the lower left panel, and were compared with changes in tumor volume (lower right panel). This comparison clearly shows that therapy effects can be observed much earlier when monitoring changes in the amplitude. At later time points, when treated tumors had decreased in volume while non-treated tumors had increased, amplitude levels reincreased in treated tumors, and were even higher than in non-treated tumors. This can be explained by the fact that resorption of central tumor parts had occurred upon antiangiogenic therapy, and that large and mature vessels from the tumor periphery had drawn closer together (reproduced from [36], with permission from Neoplasia). 
Europe PMC Funders Author Manuscripts RAD-and IgG-targeted control MB was observed using Power Doppler US; RGD-or VEGFR-2-targeted MB, on the other hand, showed prominent binding to tumor blood vessels (data from [68] ). D: Fluorescense-based molecular imaging of apoptosis and angiogenesis using FMT. In sunitinib-treated vs. non-treated A431 tumor-bearing mice, apoptosis was non-invasively investigated using Annexin Vivo 750, a near-infrared fluorescence probe that selectively binds to cell membranes during the early stages of apoptosis. Tumor vascularization was investigated using AngioSense 680, a blood pool marker. While vascularization significantly decreased in treated tumors, no enhanced annexin accumulation was observed although the gold standard TUNEL staining indicated an increased apoptosis rate (data form [76] ). E: Representative examples of longitudinal malignant glioma monitoring using 18 F-FLT PET in patients treated with bevacizumab. The FLT-uptake at baseline was determined before treatment. At later time points, 18 F-FLT PET imaging can be used to discriminate responders from non-responders and 18 F-FLT tumor uptake changes at 2 and 6 weeks were significant predictors of progression-free survival by Kaplan-Meier analysis (P < 0.001) (reprinted by permission of the Society of Nuclear Medicine from [96] , figure 1 ). 
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